Quorum Review IRB Announces Updated OnQ Web Portal
Seattle, WA
Quorum Review IRB introduced a new version of the secure OnQ™ portal. The OnQ ™ portal is a powerful information hub providing sponsors, CROs, and investigators immediate access to all Board correspondence and site start-up status information and also allows clients to submit new studies online. The OnQ™ portal now offers sorting and searching capability, making it a valuable tool for clients.
Quorum’s upgraded OnQ™ portal features an enhanced site status report that provides information on the status of site submissions, virtually real-time. In addition, the portal offers access to all Board correspondence, now in a sortable and searchable format for easy retrieval of study documents.
The portal also features a library of helpful resources, including a searchable version of Quorum’s Handbook that allows researchers to find information about Quorum policies and guidelines quickly and easily.
The upgrades to the OnQ™ portal were made with the needs of research organizations in mind, and many were the direct result of feedback that Quorum has received from portal users.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
